Conference Coverage: ASCO 2021 – FOCUS ON BREAST CANCER
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making coming out of the ASCO 2021 conference.
FACULTY CHAIR
Adam Brufsky, MD, PhD
Magee-Womens Cancer Program at the UPMC Hillman Cancer Center, Pittsburgh, PA, USA
FACULTY MEMBERS
Giuseppe Curigliano, MD, PhD
University of Milano, Milan, Italy
William Gradishar, MD
Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Nadia Harbeck, MD, PhD
Ludwig-Maximilians-University of Munich LMU – Breast Center, Germany
Mark D. Pegram, MD
Stanford Cancer Institute, Stanford, CA, USA
Paul Ellis, MD, FRACP
The London Breast Clinic, London, UK
Guy H. Jerusalem, MD, PhD
University of Liège, Liège, Belgium
Peter A. Kaufman, MD
The University of Vermont Medical Center, Burlington, VT, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Updates of Neoadjuvant Therapies in BC
- CDK4/6 Inhibitors in the Treatment of HR+/HER2– Breast Cancer
- Novel Therapeutic Approaches for HR+/HER2– Breast Cancer
- Evolving Treatments for HER2+/HR– Breast Cancer
